-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, AqIHY0qiiMoZIpNBspqPQfSF+7cTznzP2homwR7esQTxyVmLtSXzdyFTtcxpLZiK 1DXNVZaTBE7ov0gdtTeZ4w== 0001014108-02-000020.txt : 20020414 0001014108-02-000020.hdr.sgml : 20020414 ACCESSION NUMBER: 0001014108-02-000020 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20020214 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: RESPONSE ONCOLOGY INC CENTRAL INDEX KEY: 0000763098 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011] IRS NUMBER: 621212264 STATE OF INCORPORATION: TN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-37885 FILM NUMBER: 02544757 BUSINESS ADDRESS: STREET 1: 1775 MORIAH WOODS BLVD CITY: MEMPHIS STATE: TN ZIP: 38117 BUSINESS PHONE: 9017617000 MAIL ADDRESS: STREET 1: 1775 MORIAH WOODS BLVD CITY: MEMPHIS STATE: TN ZIP: 38117 FORMER COMPANY: FORMER CONFORMED NAME: BIOTHERAPEUTICS INC DATE OF NAME CHANGE: 19891221 FORMER COMPANY: FORMER CONFORMED NAME: RESPONSE TECHNOLOGIES INC DATE OF NAME CHANGE: 19920703 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: GRANT WILLIAM D CENTRAL INDEX KEY: 0000901157 STANDARD INDUSTRIAL CLASSIFICATION: UNKNOWN SIC - 0000 [0000] STATE OF INCORPORATION: MO FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: SEAFIELD CAPITAL CORPORATION STREET 2: 2600 GRAND AVENUE STE 500 CITY: KANSAS CITY STATE: MO ZIP: 64108 BUSINESS PHONE: 8168427000 MAIL ADDRESS: STREET 1: SEAFIELD CAPITAL CORP STREET 2: 2600 GRAND AVENUE SUITE 500 CITY: KANSAS CITY STATE: MO ZIP: 64108 SC 13G/A 1 lo-responcsc13g_371967.txt AMENDMENT NO. 4 TO SCHEDULE 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* RESPONSE ONCOLOGY, INC. - ------------------------------------------------------------------------------- (Name of Issuer) Common Stock, $0.01 par value per share - ------------------------------------------------------------------------------- (Title of Class of Securities) 761232 30 5 - ------------------------------------------------------------------------------- (CUSIP Number) December 31, 2001 - ------------------------------------------------------------------------------- (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: / / Rule 13d-1(b) /X/ Rule 13d-1(c) / / Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). - ------------------------------------------------------------------------------- Page 1 of 5 pages CUSIP NO. 761232 30 5 - ------------------------------------------------------------------------------- (1) Names of Reporting Persons I.R.S. Identification Nos. of Above Persons (entities only) William D. Grant - ------------------------------------------------------------------------------- (2) Check the Appropriate Box if a Member of a Group (a)/ / (b) / / Inapplicable - ------------------------------------------------------------------------------- (3) SEC Use Only - ------------------------------------------------------------------------------- (4) Citizenship or Place of Organization United States - ------------------------------------------------------------------------------- (5) Sole Voting Power 761,333 Number of Shares Beneficially --------------------------------------------------------------- Owned by (6) Shared Voting Power Each 325,194 Reporting Person --------------------------------------------------------------- With: (7) Sole Dispositive Power 761,333 --------------------------------------------------------------- (8) Shared Dispositive Power 325,194 - ------------------------------------------------------------------------------- (9) Aggregate Amount Beneficially Owned By Each Reporting Person 1,086,527 - ------------------------------------------------------------------------------- (10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares / / - ------------------------------------------------------------------------------- (11) Percent of Class Represented by Amount in Row (9) 8.8% - ------------------------------------------------------------------------------- (12) Type of Reporting Person IN - ------------------------------------------------------------------------------- Page 2 of 5 pages ITEM 1. (a) Name of Issuer: Response Oncology, Inc. (b) Address of Issuer's Principal Executive Offices: 1775 Moriah Woods Boulevard Memphis, Tennessee 38117 ITEM 2. (a) Name of Person Filing: William D. Grant (b) Address of Principal Business Office or, if none, Residence: One Ward Parkway Suite 130 Kansas City, MO 64112 (c) Citizenship: United States (d) Title of Class of Securities: Common Stock, $0.01 par value per share (e) CUSIP Number: 761232 30 5 ITEM 3. If this statement is filed pursuant to Sections 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a: Not applicable. Page 3 of 5 pages ITEM 4. Ownership. (a) Amount Beneficially Owned: 1,086,527 shares. The amount of shares reported as beneficially owned includes: (i) 168,637 shares held by three family trusts, for which the reporting person acts as co-trustee with UMB Bank, N.A., Kansas City, Missouri, and in that capacity shares voting and investment powers; (ii) 86,935 shares held by two family trusts, as to which the reporting person has the right to direct the voting and disposition of such shares, and therefore shares voting and investment powers with the trustee, UMB Bank, N.A.; (iii) 25,629 shares held by a trust for the benefit of a niece, for which the reporting person acts as co-trustee with UMB Bank, N.A., and in that capacity shares voting and investment powers, as to which shares the reporting person disclaims beneficial ownership; and (iv) 43,993 shares owned by the reporting person's wife, as to which shares the reporting person disclaims beneficial ownership. (b) Percent of Class: 8.8% (c) Number of shares as to which the person has: (i) sole power to vote or to direct the vote: 761,333 (ii) shared power to vote or to direct the vote: 325,194 (iii) sole power to dispose or to direct the disposition of: 761,333 (iv) shared power to dispose or to direct the disposition of: 325,194 ITEM 5. Ownership of Five Percent or Less of a Class. Not applicable. ITEM 6. Ownership of More Than Five Percent on Behalf of Another Person. Each trust described in Item 4(a) hereof has the right to receive and the power to direct the receipt of dividends from, or the proceeds from the sale of, 281,201 shares of Common Stock of the Issuer held by such trust. ITEM 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company. Not applicable. ITEM 8. Identification and Classification of Members of the Group. Not applicable. Page 4 of 5 pages ITEM 9. Notice of Dissolution of Group. Not applicable. ITEM 10. Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. /s/ W. D. Grant ------------------------------------------ W.D. Grant Dated: February 14, 2002 5 of 5 pages -----END PRIVACY-ENHANCED MESSAGE-----